A therapy that sends a modified cold-sore virus to selectively kill tumor cells and spark an immune response to a particularly deadly brain cancer in children showed promise in an early clinical trial, scientists reported Saturday. They hope their approach to high-grade gliomas will pave the way toward a combination treatment with immunotherapy that could spare children the harsh toxicities of current therapies.

Treatments that can enhance immune killing of cancer cells can revolutionize our approach to treating these patients,” Sriram Venetty, associate professor of pathology and neuropathology at the University of Michigan Medical School, told STAT. He was not involved in the study, whose results were presented at a virtual meeting of the American Association for Cancer Research and published in the New England Journal of Medicine on Saturday. “The data from this paper are very encouraging and provide a lead that may enable immune-viral therapies as an option to treat these deadly brain cancers in children.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]